vs

Side-by-side financial comparison of Edwards Lifesciences (EW) and Marvell Technology, Inc. (MRVL). Click either name above to swap in a different company.

Marvell Technology, Inc. is the larger business by last-quarter revenue ($2.1B vs $1.6B, roughly 1.3× Edwards Lifesciences). Marvell Technology, Inc. runs the higher net margin — 91.7% vs 23.1%, a 68.6% gap on every dollar of revenue. On growth, Marvell Technology, Inc. posted the faster year-over-year revenue change (36.8% vs 16.7%). Over the past eight quarters, Marvell Technology, Inc.'s revenue compounded faster (20.6% CAGR vs 9.7%).

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.

Marvell Technology, Inc. is an American company, headquartered in Santa Clara, California, which develops and produces semiconductors and related technology. Founded in 1995, the company had more than 6,500 employees as of 2024, with over 10,000 patents worldwide, and an annual revenue of $5.5 billion for fiscal 2024.

EW vs MRVL — Head-to-Head

Bigger by revenue
MRVL
MRVL
1.3× larger
MRVL
$2.1B
$1.6B
EW
Growing faster (revenue YoY)
MRVL
MRVL
+20.1% gap
MRVL
36.8%
16.7%
EW
Higher net margin
MRVL
MRVL
68.6% more per $
MRVL
91.7%
23.1%
EW
Faster 2-yr revenue CAGR
MRVL
MRVL
Annualised
MRVL
20.6%
9.7%
EW

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
EW
EW
MRVL
MRVL
Revenue
$1.6B
$2.1B
Net Profit
$380.7M
$1.9B
Gross Margin
78.0%
51.6%
Operating Margin
1.8%
17.2%
Net Margin
23.1%
91.7%
Revenue YoY
16.7%
36.8%
Net Profit YoY
6.8%
381.1%
EPS (diluted)
$0.66
$2.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EW
EW
MRVL
MRVL
Q1 26
$1.6B
Q4 25
$1.6B
$2.1B
Q3 25
$1.6B
$2.0B
Q2 25
$1.5B
$1.9B
Q1 25
$1.4B
$1.8B
Q4 24
$1.4B
$1.5B
Q3 24
$1.4B
$1.3B
Q2 24
$1.4B
$1.2B
Net Profit
EW
EW
MRVL
MRVL
Q1 26
$380.7M
Q4 25
$91.2M
$1.9B
Q3 25
$291.1M
$194.8M
Q2 25
$333.2M
$177.9M
Q1 25
$358.0M
$200.2M
Q4 24
$385.6M
$-676.3M
Q3 24
$3.1B
$-193.3M
Q2 24
$366.3M
$-215.6M
Gross Margin
EW
EW
MRVL
MRVL
Q1 26
78.0%
Q4 25
78.1%
51.6%
Q3 25
77.8%
50.4%
Q2 25
77.5%
50.3%
Q1 25
78.7%
50.5%
Q4 24
78.9%
23.0%
Q3 24
80.6%
46.2%
Q2 24
79.9%
45.5%
Operating Margin
EW
EW
MRVL
MRVL
Q1 26
1.8%
Q4 25
9.6%
17.2%
Q3 25
19.8%
14.5%
Q2 25
26.8%
14.3%
Q1 25
27.9%
12.9%
Q4 24
22.6%
-46.4%
Q3 24
25.9%
-7.9%
Q2 24
26.8%
-13.1%
Net Margin
EW
EW
MRVL
MRVL
Q1 26
23.1%
Q4 25
5.8%
91.7%
Q3 25
18.7%
9.7%
Q2 25
21.7%
9.4%
Q1 25
25.3%
11.0%
Q4 24
27.8%
-44.6%
Q3 24
226.7%
-15.2%
Q2 24
26.7%
-18.6%
EPS (diluted)
EW
EW
MRVL
MRVL
Q1 26
$0.66
Q4 25
$0.16
$2.20
Q3 25
$0.50
$0.22
Q2 25
$0.56
$0.20
Q1 25
$0.61
$0.23
Q4 24
$0.65
$-0.78
Q3 24
$5.13
$-0.22
Q2 24
$0.61
$-0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EW
EW
MRVL
MRVL
Cash + ST InvestmentsLiquidity on hand
$2.7B
Total DebtLower is stronger
$4.5B
Stockholders' EquityBook value
$14.1B
Total Assets
$21.6B
Debt / EquityLower = less leverage
0.32×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EW
EW
MRVL
MRVL
Q1 26
Q4 25
$4.2B
$2.7B
Q3 25
$3.8B
$1.2B
Q2 25
$4.1B
$885.9M
Q1 25
$3.9B
$948.3M
Q4 24
$4.0B
$868.1M
Q3 24
$4.4B
$808.7M
Q2 24
$2.0B
$847.7M
Total Debt
EW
EW
MRVL
MRVL
Q1 26
Q4 25
$4.5B
Q3 25
$4.5B
Q2 25
$4.2B
Q1 25
$4.1B
Q4 24
$4.1B
Q3 24
$4.1B
Q2 24
$4.1B
Stockholders' Equity
EW
EW
MRVL
MRVL
Q1 26
Q4 25
$10.3B
$14.1B
Q3 25
$10.2B
$13.4B
Q2 25
$10.5B
$13.3B
Q1 25
$10.1B
$13.4B
Q4 24
$10.0B
$13.4B
Q3 24
$9.5B
$14.2B
Q2 24
$7.4B
$14.5B
Total Assets
EW
EW
MRVL
MRVL
Q1 26
Q4 25
$13.7B
$21.6B
Q3 25
$13.3B
$20.6B
Q2 25
$13.5B
$20.0B
Q1 25
$13.0B
$20.2B
Q4 24
$13.1B
$19.7B
Q3 24
$13.0B
$20.3B
Q2 24
$10.1B
$20.5B
Debt / Equity
EW
EW
MRVL
MRVL
Q1 26
Q4 25
0.32×
Q3 25
0.33×
Q2 25
0.32×
Q1 25
0.30×
Q4 24
0.31×
Q3 24
0.29×
Q2 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EW
EW
MRVL
MRVL
Operating Cash FlowLast quarter
$582.3M
Free Cash FlowOCF − Capex
$508.8M
FCF MarginFCF / Revenue
24.5%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
0.31×
TTM Free Cash FlowTrailing 4 quarters
$1.6B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EW
EW
MRVL
MRVL
Q1 26
Q4 25
$450.9M
$582.3M
Q3 25
$573.7M
$461.6M
Q2 25
$290.2M
$332.9M
Q1 25
$280.4M
$514.0M
Q4 24
$-127.5M
$536.3M
Q3 24
$351.8M
$306.4M
Q2 24
$371.5M
$324.5M
Free Cash Flow
EW
EW
MRVL
MRVL
Q1 26
Q4 25
$353.5M
$508.8M
Q3 25
$516.2M
$414.1M
Q2 25
$240.9M
$214.1M
Q1 25
$224.4M
$444.1M
Q4 24
$-177.3M
$461.3M
Q3 24
$299.9M
$258.2M
Q2 24
$286.1M
$233.0M
FCF Margin
EW
EW
MRVL
MRVL
Q1 26
Q4 25
22.5%
24.5%
Q3 25
33.2%
20.6%
Q2 25
15.7%
11.3%
Q1 25
15.9%
24.4%
Q4 24
-12.8%
30.4%
Q3 24
22.1%
20.3%
Q2 24
20.9%
20.1%
Capex Intensity
EW
EW
MRVL
MRVL
Q1 26
Q4 25
6.2%
3.5%
Q3 25
3.7%
2.4%
Q2 25
3.2%
6.3%
Q1 25
4.0%
3.8%
Q4 24
3.6%
4.9%
Q3 24
3.8%
3.8%
Q2 24
6.2%
7.9%
Cash Conversion
EW
EW
MRVL
MRVL
Q1 26
Q4 25
4.94×
0.31×
Q3 25
1.97×
2.37×
Q2 25
0.87×
1.87×
Q1 25
0.78×
2.57×
Q4 24
-0.33×
Q3 24
0.11×
Q2 24
1.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons